Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab

[1]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[2]  D. Rimm,et al.  High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. , 2008, Human Pathology.

[3]  A. Hasso,et al.  The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. , 2008, Surgical neurology.

[4]  R. Mehta.  Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Wendland,et al.  Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. , 2008, Radiology.

[6]  M.-Y.L. Su.  Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience , 2008 .

[7]  Orhan Nalcioglu,et al.  MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy , 2008, Cancer.

[8]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[9]  M. Feldman,et al.  Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. , 2008, Biochemical pharmacology.

[10]  M. Koopman,et al.  A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[12]  A. Rossi,et al.  The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. , 2007, The oncologist.

[13]  J. Waisman,et al.  Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. , 2007, Clinical breast cancer.

[14]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Hortobagyi,et al.  Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Beth McCarville,et al.  Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.

[17]  C. Lindley,et al.  Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.

[18]  R. Christofferson,et al.  The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts , 2006, Pediatric Research.

[19]  B. Ramaswamy,et al.  Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients , 2006, Clinical Cancer Research.

[20]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[22]  F. Kabbinavar,et al.  Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[27]  Martin Vanderlaan,et al.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro , 2004, Angiogenesis.

[28]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[30]  Young Suk Park,et al.  Measuring response in solid tumors: comparison of RECIST and WHO response criteria. , 2003, Japanese journal of clinical oncology.

[31]  W. Middlesworth,et al.  Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. , 2003, Journal of pediatric surgery.

[32]  C. Balu-Maestro,et al.  Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. , 2005, Breast cancer research and treatment.

[33]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Rieber,et al.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy , 2002, European Radiology.

[35]  M. Toi,et al.  Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. , 2001, The Lancet. Oncology.

[36]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[37]  G J Metzger,et al.  MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.

[38]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[39]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[40]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[41]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.